525 filings
Page 2 of 27
6-K
x6mljm9 ivfl1psu
25 Aug 20
Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH
8:22am
6-K
nnse08h0
12 Aug 20
Current report (foreign)
4:29pm
6-K
h5p 2u3m6vom62y
5 Aug 20
Report of Foreign Private Issuer
4:27pm
6-K
0td6abmavtaey r3
27 Jul 20
Report of Foreign Private Issuer
7:09am
EFFECT
kuheoxt z6qismtyw5
27 Jul 20
Notice of effectiveness
12:16am
424B3
1flp4a
24 Jul 20
Prospectus supplement
4:30pm
CORRESP
zv6eqemko
22 Jul 20
Correspondence with SEC
12:00am
6-K
ea87 0umf
20 Jul 20
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
7:10am
D
7rrcucv
17 Jul 20
$3.41M in options / securities to be acquired, sold $3.41M, 3 investors
4:30pm
UPLOAD
eyva3e
17 Jul 20
Letter from SEC
12:00am
6-K
lunzm3 pi69x5
15 Jul 20
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
7:06am
F-1
pma42 vquvc974aiw2bd
10 Jul 20
Registration statement (foreign)
4:30pm
424B5
xi2gmjos74pnea ir5du
8 Jul 20
Prospectus supplement for primary offering
10:42am
6-K
89oxzh imue6
8 Jul 20
Report of Foreign Private Issuer
10:39am
6-K
y9eiypp2
6 Jul 20
Can-Fite Announces $3.4 Million Registered Direct Offering
8:09am
6-K
6j8p7xi4lyzzxqh
30 Jun 20
Report of Foreign Private Issuer
7:07am
6-K
c4cipo5
29 Jun 20
Notice of Special Meeting of Shareholders
12:00am
D
fpp668 cbf
19 Jun 20
$8M in options / securities to be acquired, sold $8M, 4 investors
4:35pm
SC 13G
atcignv
19 Jun 20
Can-Fite BioPharma / ARMISTICE CAPITAL ownership change
4:23pm
SC 13G
m65zp3a9w53f
19 Jun 20
Can-Fite BioPharma / CVI Investments ownership change
6:02am